Investor Alert: Kaplan Fox Investigates Perrigo Company plc (PRGO)

PR Newswire

NEW YORK, Jan. 2, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Perrigo Company plc ("Perrigo") (NYSE: PRGO) securities. Perrigo is a global healthcare company that is headquartered in Ireland, and sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

In April 2013, Elan Pharma International Limited ("Elan Pharma") (n/k/a Perrigo Pharma International) sold certain intellectual property for the drug Tysabri and related assets to Biogen Inc. ("Biogen"). The consideration paid by Biogen took the form of an upfront payment and future contingent payments. Perrigo acquired Elan Pharma through a December 2013 business combination between Perrigo's predecessor and Elan Corporation, plc.

On December 20, 2018, Perrigo filed a report with the U.S. Securities and Exchange Commission that disclosed that Perrigo Pharma International received a Notice of Amended Assessment ("NOA") issued by the Irish Office of the Revenue Commissions that assesses a tax liability against Elan Pharma in the amount of approximately €1.64 billion (approximately $1.86 billion), not including interest or penalties. The Irish Office of the Revenue Commissioners found that Elan Pharma had paid an incorrect tax rate - 12.5% instead of 33% - on proceeds from the 2013 sale of intellectual property to Biogen.

On December 20, 2018, Perrigo shares declined $15.33 per share, or approximately 30%, to close at $37.03 per share.

If you are an investor in Perrigo and would like to discuss our investigation, please contact us by emailing [email protected] or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this Notice, the action, your rights, or your interests, please contact:

Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: [email protected]

Laurence D. KingKAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California 94104
(415) 772-4700
Fax: (415) 772-4707
E-mail: [email protected]

View original content:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-investigates-perrigo-company-plc-prgo-300771867.html